PORT HUENEME, CA--(Marketwired - Oct 7, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announced today that members of its executive team will participate in panel and presentation sessions during the 6th BioMarine International Business Convention in Wilmington, NC, October 12-14, 2015 ("BioMarine").

This will be the first time BioMarine has been held in the United States. The convention brings together executives and global leaders in the biomarine sectors of major industries including biotechnology, pharmaceuticals, food, energy, and clean technology.

Catherine Brisson, Ph.D., Stellar Biotechnologies' Chief Operating Officer will participate in a panel session titled "Drugs from the Deep," a discussion of the value of the ocean for the development of new medicines and its contribution to global public health. Mark McPartland, Stellar's Vice President of Corporate Development and Communications, will present an overview of the Company's KLH business to the convention audience.

The BioMarine agenda includes live panel discussions, interactive workshops, and networking opportunities related to commercialization and partnering of marine bio-resources

About BioMarine:

BioMarine is the only international investment platform dedicated to marine bio resources. The annual convention brings together 300 international investors, entrepreneurs and executives committed to innovation and collaboration in this growing global sector. In addition to acting as a platform for meetings and exchanges between industry professionals, BioMarine is above all the strategic center of action and initiatives for key stakeholders in the marine bio resources industry. Finance, research and industry stakeholders have learned to use the platform to diversify their knowledge, strengthen their existing partnerships and build new opportunities. To learn more, visit http://biomarine.org/.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.

Contact Information:

Stellar Biotechnologies Company Contact:
Mark A. McPartland
Vice President of Corporate Development and Communications
Phone: +1 (805) 488-2800 ext. 103

Investor Inquiries:
Joseph Green
The Ruth Group
Phone: +1 (646) 536-7013

Media Inquiries:
Joanna Zimmerman
The Ruth Group
Phone: +1 (646) 536-7006